Janjigian YY - Search Results

1

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. Janjigian YY, et al. Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. Lancet. 2021. PMID: 34102137 Free PMC article. Clinical Trial.

2

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ. Janjigian YY, et al. Clin Cancer Res. 2011 Apr 15;17(8):2521-7. doi: 10.1158/1078-0432.CCR-10-2662. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248303 Clinical Trial.

3

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Janjigian YY, et al. Ann Oncol. 2012 Oct;23(10):2656-2662. doi: 10.1093/annonc/mds104. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689179 Free article.

4

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Janjigian YY, et al. Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f. Am J Clin Oncol. 2014. PMID: 23211227 Clinical Trial.

5

Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.

Gerber N, Ilson DH, Wu AJ, Janjigian YY, Kelsen DP, Zheng J, Zhang Z, Bains MS, Rizk N, Rusch VW, Goodman KA. Gerber N, et al. Among authors: janjigian yy. Dis Esophagus. 2014 Apr;27(3):235-41. doi: 10.1111/dote.12082. Epub 2013 Jun 24. Dis Esophagus. 2014. PMID: 23796070

6

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS. Park DJ, et al. Among authors: janjigian yy. Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27. Ann Surg Oncol. 2014. PMID: 24370903

7

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Janjigian YY, et al. PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015. PLoS One. 2015. PMID: 26275293 Free PMC article. Clinical Trial.

8

Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Ku GY, et al. Among authors: janjigian yy. Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6. Cancer. 2016. PMID: 27152857 Free PMC article.

9

It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma.

Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. Elimova E, et al. Among authors: janjigian yy. J Clin Oncol. 2017 Feb;35(4):475-477. doi: 10.1200/JCO.2016.69.7276. Epub 2016 Oct 28. J Clin Oncol. 2017. PMID: 28129519 No abstract available.

10

New agents on the horizon in gastric cancer.

Lordick F, Shitara K, Janjigian YY. Lordick F, et al. Among authors: janjigian yy. Ann Oncol. 2017 Aug 1;28(8):1767-1775. doi: 10.1093/annonc/mdx051. Ann Oncol. 2017. PMID: 28184417 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page